Before raising venture capital for Mirror, founder Bryn Putnam bootstrapped the initial year of R&D using profits from her four successful fitness studios. This provided non-dilutive capital and a safety net, allowing her to explore the high-risk hardware concept without immediate investor pressure.

The old model of raising a large sum of money to build infrastructure is obsolete. Today, founders can and should validate their product and find customers with minimal capital *before* seeking significant investment, reversing the traditional order of operations.

For early-stage MedTech startups, key milestones for investors are not just regulatory successes. They are fundamental proofs of concept—showing the device works in a model and demonstrating how it would function in a clinical setting. This builds an investor's vision of the product's future.

Avoid the classic bootstrap vs. raise dilemma by using customer financing. Pre-sell your product or service to a group of early customers. This strategy not only provides the necessary starting capital without giving up equity but also serves as the ultimate form of market validation.

Instead of hoarding early capital, Actuate's CEO synthesized a kilogram of their molecule and sent it to labs worldwide. The goal was to fail fast by seeing if promising results could be replicated, a crucial de-risking step before committing larger funds.

VC funding provides crucial leverage for securing non-dilutive grants. Many government grants operate on a reimbursement basis, requiring startups to spend capital first. Venture funding provides this necessary upfront cash, enabling hardware companies to access a powerful, complementary source of capital.

Repro Novo's co-founders invested their own money for the costly process of finding and negotiating assets. This allowed them to secure a promising candidate before approaching institutional investors, demonstrating strong conviction and de-risking the initial investment for VCs.

The company adopted a phased approach, using initial seed funding to de-risk the program by focusing narrowly on manufacturing (CMC) and regulatory hurdles to clear its IND. This milestone-driven strategy made it a more attractive investment for a larger Series A intended to fund clinical trials.

Validate market demand by securing payment from customers before investing significant resources in building anything. This applies to software, hardware, and services, completely eliminating the risk of creating something nobody wants to buy.